MSC activity could be modulated in a variety of ways using, among others, drugs that inhibit one or, preferably, several of the MSC‐derived immunosuppressive molecules (e.g. IDO, TGF‐β); inhibitory antibodies (e.g. anti‐PDGF, anti‐EGFR antibodies) that block the effect of growth factors involved in MSC–tumor cell crosstalk 233, 234, 235 and elicit ADCC (antibody‐dependent cellular cytotoxicity); inhibitors of sheddases/ADAMs (a disintegrin and metalloproteinases); and tyrosine kinase inhibitors. Here, TGFB1 is linked to neoplasm.